Status:
COMPLETED
Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma
Lead Sponsor:
Michael C Roarke, MD
Conditions:
Multiple Myeloma
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance ...
Detailed Description
Participants who are clinically scheduled to undergo F-18 FDG PET/CT myeloma evaluation will also undergo F-18 FDG PET/MRI, and C-11 acetate PET CT/MRI. On Day 1 of study, participants will undergo F-...
Eligibility Criteria
Inclusion
- Patients being staged for multiple myeloma as follows: new diagnosis, high risk smoldering multiple myeloma, relapsed as defined by investigator
- Patients who have undergone standard of care workup
- 300 pounds or less
- Can provide informed consent
- Scheduled for a clinically indicated F-18 FDG PET scan
- English speaking
Exclusion
- Pregnant, breast feeding
- Concurrent active non-multiple myeloma malignancy
- Contraindication to PET MRI
- Previous Type I or Type II Diabetes mellitus or a fasting blood glucose \>150 mg/dl
Key Trial Info
Start Date :
September 19 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 23 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03262389
Start Date
September 19 2017
End Date
November 23 2019
Last Update
March 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259